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ABSTRACT Chronic spontaneous urticaria can be treated with several 
drugs such as antihistamines, leukotriene antagonists, cyclosporine, dox-
epin, hydroxychloroquine, colchicine, and corticosteroids. However, treat-
ment-resistant urticaria significantly reduces quality of life. In recent years, 
omalizumab has been considered to be an effective treatment option in 
treatment-resistant cases. We aimed to investigate the clinical efficacy of 
omalizumab in urticaria and its possible association with serum IgE levels, 
total eosinophil counts, and basophil percentages. Medical records of 11 
patients with chronic spontaneous urticaria treated with omalizumab were 
reviewed retrospectively. Treatment response, urticaria activity score, se-
rum basophil percentages, eosinophil, and IgE levels evaluated before and 
at the end of the therapy. Ten patients healed completely with omalizum-
ab. One patient did not respond to therapy. No correlation was observed 
between serum IgE levels and treatment outcome. However, serum eo-
sinophil levels decreased and basophil percentages increased with omali-
zumab treatment. Omalizumab is a safe and effective treatment choice in 
patients with chronic spontaneous urticaria. We suggest that omalizumab 
may have an effect in the treatment of urticaria through eosinophils.
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INTRODUCTION
Omalizumab is a monoclonal antibody which 
binds to high-affinity IgE receptors. A decrease in se-
rum free IgE levels of up to 90% can be observed at 
the end of the 16-24 weeks of omalizumab therapy 
in patients with asthma (1). It has been suggested 
that decreased IgE levels lead to down-regulation 
of expression of high-affinity IgE receptors on baso-
phils and mast cells (1). Furthermore, omalizumab 
has an effect of disintegration of IgE from basophil 
and mast cells (1). Chronic urticaria presents with 
pruritic wheals that last more than six weeks (2). 
Chronic urticaria can be divided into chronic spon-
taneous urticaria and chronic inducible urticaria. 
Chronic spontaneous urticaria describes chronic 
urticaria without any external stimulus (3). It is not 
always easy to treat patients with chronic urticaria. 
The disease decreases quality of life at least as much 
as ischemic heart disease does (2). Omalizumab is 
widely used in Europe and the United States for the 
treatment of patients with chronic spontaneous ur-
ticaria who do not response to high doses of antihis-
tamines (4).
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In this study, we aimed to investigate the effect of 
omalizumab in the treatment of patients with treat-
ment resistant chronic spontaneous urticaria and to 
look for a possible association with serum IgE levels 
and total eosinophil or basophil levels.
PATIENTS AND METHODS
The study was approved by the local ethic com-
mittee. Medical records of the patients with chronic 
spontaneous urticaria were reviewed retrospectively. 
Eleven patients (2 male, 9 female) with chronic spon-
taneous urticaria treated with omalizumab between 
January 2014 and March 2017 were included in the 
study. The age range was between 19 and 59. The 
average duration of disease was 44.7 months (4-146 
months). All the patients were previously treated 
with high-dose oral antihistamines. The median dura-
tion of antihistamine therapy was six months (range 
2-12 months). Moreover, four patients had received 
systemic steroids for two months and one patient re-
ceived doxepin for two months and montelukast for 
one month without benefit. 
Serum total IgE levels, serum total eosinophil 
counts, serum eosinophil and basophil percentages, 
and urticaria activity scores were evaluated before 
and at the end of the administration of the last dose 
of omalizumab therapy. Omalizumab in a dose of 300 
mg was administered by subcutaneous injection ev-
ery 4 weeks. The treatment was stopped when no re-
sponse was observed despite four sessions of omali-
zumab therapy.
Clinical response and disease severity were evalu-
ated using the urticaria activity score (UAS) which 
was assessed as the sum of itch severity and hive 
count occurring over 24 hours as described below 
(5). Pruritus which was not reported as annoying was 
regarded as mild; pruritus which did not interfere 
with normal daily activity was regarded as moderate; 
pruritus which interfered with normal daily activity or 
sleep was regarded as severe pruritus. Urticaria activ-
ity scores 0 and 1 (mild pruritus without any hives) 
were classified as a complete response to omalizum-
ab therapy. 




Before       After
therapy   therapy
Serum total IgE 
levels
(IU/mL)
 Before        After 




Before          After
therapy     therapy
Serum basophil 
percentages (%)
 Before      After 
therapy   therapy
Omalizumab
Dose
1* 6 1 171.9 125.5 68 40 0.58 0.44 5
2* 6 0 129.1 613 109 97 0.72 0.73 6
3* 6 1 107.8 494.8 206 193 1.13 1.24 7
4* 6 1 339.6 165.1 60 48 0.47 0.61 8
5* 4 1 549 250 230 149 1.03 0.78 8
6* 6 1 443.2 464.7 90 144 0.92 1.2 8
7* 5 0 169.8 443 193 109 0.84 0.92 8
8† 5 0 2068 2131 300 302 1.65 1.84 13
9† 5 0 97 396.7 80 55 0.93 1.65 22
10† 6 1 25 98 131 180 1.42 1.53 20
11‡ 5 5 25 136 190 166 1.22 0.98 4
* Well responders to omalizumab therapy
† Recurrent cases after cessation of treatment
‡ The patient who did not respond to therapy
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0: No pruritus/hives
1: Mild pruritus/hive count <20
2: Moderate pruritus/hive count: 20-50
3: Severe pruritus/hive count> 50 (5).
We used SPSS 22 for data analysis. The Wilcoxon 
two-sample test was used to compare results before 
and after treatment.
RESULTS
Three (27.7%) of 11 patients were still to receiv-
ing omalizumab therapy at the time of the study. 
The treatment course for these patients was 13, 20, 
and 22 months. After eight months of therapy, hav-
ing achieved complete remission, omalizumab was 
discontinued. However, urticarial lesions reoccurred. 
These three patients were returned to omalizumab 
within two months. Serum total IgE levels increased 
in two patients and stayed similar in one patient after 
omalizumab therapy. Serum total eosinophil levels 
increased in one, decreased in one, and stayed simi-
lar in the third patient. However, serum basophil per-
centage increased in all three patients (Table 1).
Four (36.6%) of 11 patients received a total of eight 
sessions of omalizumab 300 mg every four weeks. 
Therapy was stopped at the end of the eighth month 
and no recurrence was observed during six-month 
follow up. Serum total IgE levels increased in one pa-
tient, decreased in two of these patients, and stayed 
similar in one patient after omalizumab therapy. Se-
rum eosinophil levels decreased in three patients and 
increased in one patient. However, basophil percent-
age increased in three patients and decreased in one 
patient.
Three (27.2%) of 11 patients received a total of 
five, six, and seven sessions of omalizumab, respec-
tively. Therapy achieved complete remission in these 
patients without recurrence. Serum total IgE levels 
increased in two of these patients and decreased in 
one patient. Serum eosinophil levels decreased in all 
three patients. Serum basophil percentage increased 
in one patient, decreased in one, and stayed similar in 
the third patient.
Serum total IgE levels decreased in three (27.7%) 
patients, increased in six (54.5%) patients, and stayed 
similar in two (18.1%) patients (Table 2).
Serum total eosinophil levels decreased in eight 
(72.7%) patients, increased in two (18.1%) patients, 
and stayed similar in one (9%) patient (Table 3).
Serum basophil percentages decreased in three 
(27.7%) patients, increased in seven (63.6%) patients, 
and stayed similar in one (9%) patient (Table 1).
All patients except one showed complete re-
sponse to omalizumab therapy. Additionally, three 
patients were still on omalizumab therapy. The com-
plete clinical response of omalizumab therapy was 
achieved in eight (72.7%) of 11 patients at four weeks 
and two (18.1%) of patients at eight weeks. One pa-
tient did not respond to the treatment despite a total 
of four sessions of omalizumab therapy. The urticaria 
activity score of the patient who failed treatment was 
5 both before and at the end of the omalizumab ther-
apy (Table 4). The serum total IgE level of this patient 
increased, while total serum eosinophil count and 
serum basophil percentage were decreased at the 
end of the second dose of omalizumab. In addition to 
urticaria, the patient was diagnosed with atopic der-
matitis in childhood. Furthermore, she was allergic to 
bee venom.
The mean follow-up time was ten months (range: 
4-22 months) during therapy. No adverse reaction 
were observed in patients during the omalizumab 
therapy or follow-up. 
DISCUSSION
Basophils seem to play an important role in the 
pathogenesis of chronic spontaneous urticaria. It 
Table 2. The effect of omalizumab on serum IgE lev-
els (IU/mL)
Table 3. The effect of omalizumab on serum eosino-
phil levels 
Tamer et al. Acta Dermatovenerol Croat
Omalizumab in patients with CSU 2019;27(2):101-106
104 ACTA DERMATOVENEROLOGICA CROATICA
Table 4. The effect of omalizumab on urticaria activ-
ity score. 
The urticaria activity scores of the patients numbered 
2, 7, 8, and 9 were 0 after therapy. 
has been suggested that patients with urticaria tak-
ing omalizumab treatment have gradually decreased 
serum basophil levels as a result of migration of ba-
sophils into the tissues. Therefore, basopenia may be 
correlated with treatment response. Saini et al. inves-
tigated the effect of omalizumab on serum basophil 
levels in patients with chronic urticaria. Patients tak-
ing omalizumab 75 mg, 150 mg, 300 mg, or placebo 
were included in the study. Serum basophil levels 
were measured at baseline and every 12 weeks af-
ter the first dose and compared between these four 
groups. Baseline basophil blood percentages were 
similar in all groups. However, basophil percentages 
were higher in patients treated with omalizumab 
when compared with the placebo group at weeks 
12 and 24. Increase in serum basophil percentage 
was significant in patients taking omalizumab 300 
mg monthly. Omalizumab was effective in all treat-
ment groups, most notably in patients taking 300 mg 
omalizumab per month. Increase in circulating baso-
phils was proposed as a marker of clinical response to 
omalizumab in patients with urticaria. Omalizumab 
probably inhibits the migration of basophils from cir-
culation into the tissues. Therefore, it increases serum 
levels of basophils (6). 
Although the main step in all types of urticaria is 
activation and degranulation of basophils and mast 
cells, it has been suggested that eosinophils also play 
an important role in the etiopathogenesis of chronic 
urticaria (7). In patients with chronic urticaria, vascular 
endothelial growth factor (VEGF) is mainly produced 
by eosinophils. Vascular endothelial growth factor in-
creases vascular permeability, induces angiogenesis, 
and has a vasodilatory effect on endothelial cells. It 
thus causes wheals, flare reaction, and angioedema 
(7). Besides producing tissue-damaging molecules, 
eosinophils lead urticaria by releasing pro-inflamma-
tory and immunoregulatory proteins (8). Eosinophil 
cationic protein, eosinophil-derived neurotoxin, and 
major basic protein are cationic proteins released by 
eosinophils. They lead to epithelial damage in tis-
sues. Skin samples of patients with chronic urticaria 
showed deposition of major basic protein and eosin-
ophil cationic protein outside the eosinophils. These 
proteins have been reported to increase histamine 
release from basophils and mast cells (8).
Omalizumab is a recombinant humanized mono-
clonal antibody which has an anti-IgE effect. It pre-
vents free IgE antibodies from binding to the re-
ceptors on B cells, dendritic cells, eosinophils, and 
monocytes (9,10). It also reduces IgE receptor expres-
sion on basophils, mast cells, and dendritic cells (11). 
Moreover, it leads to B cell anergia and reduces IgE 
synthesis. It has been suggested that omalizumab 
induces eosinophil apoptosis (12,13). However, the 
mechanism remains controversial. It may be due to 
the direct effect of the drug. On the other hand, eo-
sinophil apoptosis may occur as a result of reduction 
of IgE and T-cell-derived cytokines (14).
High-affinity IgE receptors in dendritic cells pres-
ent antigens and activate T lymphocytes. However, 
it is controversial whether high-affinity IgE receptor 
signaling stimulates cytokine and chemokine synthe-
sis and enhances inflammation. Furthermore, some 
studies suggest an immune suppressive effect of the 
signaling by inducing anti-inflammatory cytokines 
like IL-10. Omalizumab may inhibit the allergic/in-
flammatory pathway by suppressing antigen presen-
tation and IgE-IgE receptor binding in dendritic cells 
(15).
Metz et al. retrospectively investigated the effect 
of omalizumab in 51 patients with chronic urticaria. 
They defined complete response as a >90% reduction 
of lesions. Total serum IgE levels, autologous serum 
skin test results, and skin prick tests were examined. 
83% of the patients showed complete remission. Mild 
cutaneous angioedema was observed in one patient 
after omalizumab injection. They reported no correla-
tion between total serum IgE levels, autologous se-
rum skin test results, skin prick test results, and treat-
ment response. Serum tryptase level was measured 
as a marker of mast cell activation. No significant 
difference was observed between baseline serum 
tryptase levels and levels at 2-4 weeks after treatment 
(16). However, Ertas et al. reported that total serum 
IgE levels can predict the response to omalizumab 
in patients with chronic spontaneous urticaria. The 
patients with chronic spontaneous urticaria who did 
not response to omalizumab therapy had significant-
ly lower serum IgE levels compared with partial and 
complete responders (17).
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Skiepko et al. analysed the changes of serum eo-
sinophilia after 4-month of omalizumab therapy in 
patients with severe allergic asthma. They found that 
patients with higher decrease in blood eosinophilia 
had lower asthma exacerbations during omalizumab 
therapy (18). Clinical efficacy of omalizumab in asth-
ma is proportional to increased level of peripheral 
eosinophilia. Therefore, anti-eosinophilic effect of 
omalizumab may be as important as the anti-IgE ef-
ficacy of omalizumab, especially in the treatment of 
patients with non-allergic asthma (19). Nevertheless, 
it should be kept in mind that the role of eosinophils 
may differ in urticaria which is not an allergic disease 
and in severe asthma which is mostly connected with 
allergy.
In our study, all patients except one showed ex-
cellent clinical improvement with omalizumab treat-
ment. Sustained clinical remission was obtained in 
72.7% patients within four weeks. However, serum 
IgE levels did not correlate with clinical outcome. 
Approximately half of the patients showed elevated 
serum IgE levels at the end of the therapy when com-
pared with baseline IgE levels, while others showed 
decreased serum IgE levels. However, serum total eo-
sinophil count showed a steady decrease and serum 
basophil percentage showed an increase in most of 
the patients. Decrease in total eosinophil count can 
be explained by eosinophil apoptosis induced by 
omalizumab, which may be parallel to clinical re-
sponse. On the other hand, increase in serum baso-
phil percentage may occur as a result of inhibition 
of basophil migration from circulation to the skin by 
omalizumab.
CONCLUSION
Omalizumab has high efficacy in the treatment of 
chronic spontaneous urticaria irresponsive to classi-
cal treatment options. We suggest that eosinophils 
and basophils might play a much more important 
role than serum IgE levels in the pathogenesis and 
treatment of chronic spontaneous urticaria with 
omalizumab. Therefore, serum eosinophil count may 
be a marker in the follow-up of patients receiving 
omalizumab treatment, facilitating decisions regard-
ing dosage or cessation of treatment.
References:
1.  Metz M, Staubach P, Bauer A, Brehler R, Gericke J, 
Kangas M, et al. Clinical efficacy of omalizumab in 
chronic spontaneous urticaria is associated with a 
reduction of FcεRI-positive cells in the skin. Thera-
nostics. 2017;7:1266-76.
2.  Rutkowski K, Grattan CEH. How to manage chro-
nic urticaria ‘beyond’ guidelines: a practical algo-
rithm. Clin Exp Allergy. 2017;47:710-8.
3.  Godse K, De A, Zawar V, Shah B, Girdhar M, Ra-
jagopalan M, et al. Consensus Statement for the 
Diagnosis and Treatment of Urticaria: A 2017 Up-
date. Indian J Dermatol. 2018;63:2-15.
4.  Hide M, Park HS, Igarashi A, Ye YM, Kim TB, Yagami 
A, et al. Efficacy and safety of omalizumab in Japa-
nese and Korean patients with refractory chronic 
spontaneous urticaria. J Dermatol Sci. 2017;87:70-
8.
5.  Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, 
Brzoza Z, Canonica GW, et al. The EAACI/GA2LEN/
EDF/WAO Guideline for the definition, classifica-
tion, diagnosis, and management of urticaria: the 
2013 revision and update. Allergy. 2014;69:1-29.
6.  Saini SS, Omachi TA, Trzaskoma B, Hulter HN, Ro-
sén K, Sterba PM, et al. Effect of omalizumab on 
blood basophil counts in patients with chronic 
idiopathic/spontaneous urticaria. J Invest Derma-
tol. 2017;137:958-61.
7. Asero R, Cugno M, Tedeschi A. Eosinophils in chro-
nic urticaria: supporting or leading actors? World 
Allergy Organ J. 2009;2:213-7.
8. Staumont-Sallé D, Dombrowicz D, Capron M, 
Delaporte E. Eosinophils and urticaria. Clin Rev Al-
lergy Immunol. 2006;30:13-8.
9.  Eggel A, Baravalle G, Hobi G, Kim B, Buschor P, For-
rer P, et al. Accelerated dissociation of IgE-Fcepsi-
lonRI complexes by disruptive inhibitors actively 
desensitizes allergic effector cells. J Allergy Clin 
Immunol. 2014;133:1709-19.e8.
10. Serrano-Candelas E, Martinez-Aranguren R, Valero 
A, Bartra J, Gastaminza G, Goikoetxea MJ, et al. 
Comparable actions of omalizumab on mast cells 
and basophils. Clin Exp Allergy. 2016;46:92-102.
11. Incorvaia C, Mauro M, Russello M, Formigoni C, 
Riario-Sforza GG, Ridolo E. Omalizumab, an anti-
immunoglobulin E antibody: state of the art. Drug 
Des Devel Ther. 2014;8:197-207.
12. Chan MA, Gigliotti NM, Dotson AL, Rosenwasser 
LJ. Omalizumab may decrease IgE synthesis by 
targeting membrane IgE+ human B cells. Clin 
Transl Allergy. 2013;3:29.   
13. Noga O, Hanf G, Brachmann I, Klucken AC, Kleine-
Tebbe J, Rosseau S, et al. Effect of omalizumab 
treatment on peripheral eosinophil and T-lymp-
hocyte function in patients with allergic asthma. 
J Allergy Clin Immunol. 2006;117:1493-9.  
14. Navinés-Ferrer A, Serrano-Candelas E, Molina-
Molina GJ, Martín M. IgE-related chronic diseases 
Tamer et al. Acta Dermatovenerol Croat
Omalizumab in patients with CSU 2019;27(2):101-106
106 ACTA DERMATOVENEROLOGICA CROATICA
and anti-Ige-based treatments. J Immunol Res. 
2016;2016:8163803.   
15. Shin JS, Greer AM. The role of FcεRI expressed in 
dendritic cells and monocytes. Cell Mol Life Sci. 
2015;72:2349-60.   
16. Metz M, Ohanyan T, Church MK, Maurer M. Oma-
lizumab is an effective and rapidly acting therapy 
in difficult-to-treat chronic urticaria: a retrospecti-
ve clinical analysis. J Dermatol Sci. 2014;73:57-62.
17. Ertas R, Ozyurt K, Atasoy M, Hawro T, Maurer M. 
The clinical response to omalizumab in chronic 
spontaneous urticaria patients is linked to and 
predicted by IgE levels and their change. Allergy. 
2018;73:705-12.
18. Skiepko R, Ziętkowski Z, Łukaszyk M, Budny W, 
Skiepko U, Milewski R, et al. Changes in blood eo-
sinophilia during omalizumab therapy as a pre-
dictor of asthma exacerbation. Postepy Dermatol 
Alergol. 2014;31:305-9.
19. Kupryś-Lipińska I, Molińska K, Kuna P. The effect of 
omalizumab on eosinophilic inflammation of the 
respiratory tract in patients with allergic asthma. 
Pneumonol Alergol Pol. 2016; 84: 232-43.
Tamer et al. Acta Dermatovenerol Croat
Omalizumab in patients with CSU 2019;27(2):101-106
